An observational study in Breast Cancer, sponsored by AstraZeneca. Completed at 12 sites in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-03-09.
Sponsored by AstraZeneca · Observational
To investigate the global incidence of the endometrial changes in postmenopausal women receiving Anastrozole for the adjuvant treatment of hormone receptors positive breast cancer.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's enrollment of 165 is below the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Medical Oncology
Exclusion Criteria:
Women with hormone receptor positive breast cancer under adjuvant treatment with Anastrozole
Global incidence of endometrial changes during the adjuvant treatment with Anastrozole
Time frame: From inclusion to treatment end(5 years duration) measurements will be taken annually, with a further assessment 12 months after end of treatment.
To describe the endometrial changes both clinically(vaginal bleeding) and through the scan.
Time frame: During the study, at least annually
Histological assessment when indicated(type of hyperplasia)
Time frame: When applicable
To assess global incidence of endometrial changes in this patient population before taking Anastrozole
Time frame: During the study
To evaluate type of surgery required for endometrial changes control(hysterectomy rate)
Time frame: During the study
To assess treatment tolerability
Time frame: During the study
This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca